|
US9718796B2
(en)
|
2011-01-12 |
2017-08-01 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
US10548985B2
(en)
|
2014-01-10 |
2020-02-04 |
Birdie Biopharmaceuticals, Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
|
US10413565B2
(en)
|
2014-04-30 |
2019-09-17 |
Northwestern University |
Nanostructures for modulating intercellular communication and uses thereof
|
|
CA2953216C
(en)
|
2014-06-04 |
2020-12-22 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
CA2954446A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN107002081A
(zh)
|
2014-10-06 |
2017-08-01 |
埃克西奎雷股份有限公司 |
抗tnf化合物
|
|
EP3233835B1
(en)
*
|
2014-12-18 |
2019-01-23 |
F.Hoffmann-La Roche Ag |
Benzazepine sulfonamide compounds
|
|
EP3722297A1
(en)
|
2015-03-04 |
2020-10-14 |
Gilead Sciences, Inc. |
Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
|
|
SI3265458T1
(sl)
*
|
2015-03-06 |
2019-03-29 |
F. Hoffmann-La Roche Ag |
Benzazepin dikarboksamidne spojine
|
|
WO2016149323A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Exicure, Inc. |
Immunomodulatory spherical nucleic acids
|
|
CA2995004A1
(en)
|
2015-08-26 |
2017-03-02 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
|
JP6732915B2
(ja)
|
2015-12-15 |
2020-07-29 |
ギリアード サイエンシーズ, インコーポレイテッド |
ヒト免疫不全ウイルス中和抗体
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
HRP20220577T1
(hr)
*
|
2016-05-06 |
2022-06-24 |
Shanghai De Novo Pharmatech Co., Ltd. |
Derivat benzazepina, metoda pripreme, farmaceutski sastav i njegova upotreba
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
WO2017205078A1
(en)
|
2016-05-27 |
2017-11-30 |
Gilead Sciences, Inc. |
Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
|
|
US10071079B2
(en)
|
2016-06-29 |
2018-09-11 |
Bristol-Myers Squibb Company |
[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
|
|
CA3031675A1
(en)
|
2016-07-30 |
2018-02-08 |
Bristol-Myers Squibb Company |
Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
ES2906581T3
(es)
|
2016-09-02 |
2022-04-19 |
Gilead Sciences Inc |
Compuestos moduladores de los receptores tipo Toll
|
|
WO2018049089A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Pyridyl substituted indole compounds
|
|
BR112019007450A2
(pt)
|
2016-10-14 |
2020-07-07 |
Precision Biosciences, Inc. |
meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b
|
|
TWI714820B
(zh)
|
2017-01-31 |
2021-01-01 |
美商基利科學股份有限公司 |
替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
JP2020514419A
(ja)
|
2017-03-15 |
2020-05-21 |
シルバーバック セラピューティックス インコーポレイテッド |
ベンズアゼピン化合物、そのコンジュゲート及び使用
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
|
JP7104775B2
(ja)
|
2017-08-04 |
2022-07-21 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tlr7/8/9の阻害剤として有用な置換インドール化合物
|
|
JP7266576B2
(ja)
|
2017-08-04 |
2023-04-28 |
ブリストル-マイヤーズ スクイブ カンパニー |
[1,2,4]トリアゾロ[4,3-a]ピリジニル置換のインドール化合物
|
|
AR112413A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas sólidas de un inhibidor de la cápside del vih
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
AU2018319538B9
(en)
|
2017-08-22 |
2021-05-27 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
CN109694351B
(zh)
*
|
2017-10-23 |
2020-07-28 |
江苏恒瑞医药股份有限公司 |
苯并氮杂*衍生物、其制备方法及其在医药上的应用
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
WO2019099336A1
(en)
|
2017-11-14 |
2019-05-23 |
Bristol-Myers Squibb Company |
Substituted indole compounds
|
|
KR102781141B1
(ko)
|
2017-12-15 |
2025-03-13 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 인돌 에테르 화합물
|
|
JP2021506827A
(ja)
|
2017-12-15 |
2021-02-22 |
シルバーバック セラピューティックス インコーポレイテッド |
肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
|
|
LT3728252T
(lt)
|
2017-12-18 |
2023-10-25 |
Bristol-Myers Squibb Company |
4-azaindolo junginiai
|
|
AU2018390820A1
(en)
|
2017-12-19 |
2020-08-06 |
Bristol-Myers Squibb Company |
Substituted indole compounds useful as TLR inhibitors
|
|
SG11202005700SA
(en)
|
2017-12-19 |
2020-07-29 |
Bristol Myers Squibb Co |
Amide substituted indole compounds useful as tlr inhibitors
|
|
SG11202005704RA
(en)
|
2017-12-19 |
2020-07-29 |
Bristol Myers Squibb Co |
6-azaindole compounds
|
|
ES2904773T3
(es)
|
2017-12-20 |
2022-04-06 |
Bristol Myers Squibb Co |
Compuestos de diazaindol
|
|
CN111566120B
(zh)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
|
|
BR112020011984A2
(pt)
|
2017-12-20 |
2020-11-17 |
Bristol-Myers Squibb Company |
compostos de amino indol úteis como inibidores de tlr
|
|
KR102730859B1
(ko)
|
2017-12-20 |
2024-11-15 |
브리스톨-마이어스 스큅 컴퍼니 |
아릴 및 헤테로아릴 치환된 인돌 화합물
|
|
EP3728282B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111712494A
(zh)
|
2018-02-13 |
2020-09-25 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
KR102587510B1
(ko)
|
2018-02-15 |
2023-10-11 |
길리애드 사이언시즈, 인코포레이티드 |
피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
|
|
CA3281991A1
(en)
|
2018-02-16 |
2025-11-29 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
|
|
CA3091142C
(en)
|
2018-02-26 |
2023-04-11 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
EP4600247A3
(en)
|
2018-04-19 |
2025-11-19 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
SG11202012043RA
(en)
|
2018-07-03 |
2021-01-28 |
Gilead Sciences Inc |
Antibodies that target hiv gp120 and methods of use
|
|
KR102651420B1
(ko)
|
2018-07-06 |
2024-03-28 |
길리애드 사이언시즈, 인코포레이티드 |
치료 헤테로시클릭 화합물
|
|
CN112384283B
(zh)
|
2018-07-06 |
2023-08-15 |
吉利德科学公司 |
治疗性的杂环化合物
|
|
KR20230159715A
(ko)
|
2018-07-13 |
2023-11-21 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
JP2021530523A
(ja)
|
2018-07-16 |
2021-11-11 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivの処置のためのカプシド阻害剤
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
AU2019337654A1
(en)
*
|
2018-09-12 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Substituted benzazepine compounds, conjugates, and uses thereof
|
|
SG11202101980VA
(en)
|
2018-09-12 |
2021-03-30 |
Silverback Therapeutics Inc |
Methods and composition for the treatment of disease with immune stimulatory conjugates
|
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
CN112955450A
(zh)
|
2018-10-24 |
2021-06-11 |
百时美施贵宝公司 |
经取代的吲哚和吲唑化合物
|
|
KR20210080462A
(ko)
|
2018-10-24 |
2021-06-30 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 인돌 이량체 화합물
|
|
CN117105933A
(zh)
|
2018-10-31 |
2023-11-24 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
|
CN113227089B
(zh)
|
2018-10-31 |
2024-07-05 |
吉利德科学公司 |
作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
|
|
JP7287708B2
(ja)
|
2019-02-08 |
2023-06-06 |
プロジェニア インコーポレイテッド |
Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
SI3938047T1
(sl)
|
2019-03-22 |
2022-10-28 |
Gilead Sciences, Inc. |
Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
|
|
SG11202110401WA
(en)
*
|
2019-04-09 |
2021-10-28 |
Hoffmann La Roche |
Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020227484A1
(en)
|
2019-05-09 |
2020-11-12 |
Bristol-Myers Squibb Company |
Substituted benzimidazolone compounds
|
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
MX2021015533A
(es)
|
2019-06-19 |
2022-02-10 |
Silverback Therapeutics Inc |
Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
|
|
JP7295283B2
(ja)
|
2019-06-25 |
2023-06-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
Flt3l-fc融合タンパク質及び使用方法
|
|
JP7454645B2
(ja)
|
2019-07-16 |
2024-03-22 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivワクチン並びにその作製方法及び使用方法
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
MX2022001719A
(es)
|
2019-08-15 |
2022-03-11 |
Silverback Therapeutics Inc |
Formulaciones de conjugados de benzazepina y usos de las mismas.
|
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
HRP20241379T1
(hr)
|
2019-09-30 |
2024-12-20 |
Gilead Sciences, Inc. |
Cjepiva za hbv i postupci za liječenje hbv
|
|
WO2021067644A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
WO2021067326A1
(en)
|
2019-10-01 |
2021-04-08 |
Bristol-Myers Squibb Company |
Substituted bicyclic heteroaryl compounds
|
|
EP4038059B1
(en)
|
2019-10-04 |
2023-09-20 |
Bristol-Myers Squibb Company |
Substituted carbazole compounds
|
|
EP4045083B1
(en)
|
2019-10-18 |
2024-01-10 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
EP4051387B1
(en)
|
2019-10-31 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
US12486273B2
(en)
|
2019-11-19 |
2025-12-02 |
Hoffmann-La Roche Inc. |
Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
|
|
EP4643882A2
(en)
|
2019-11-26 |
2025-11-05 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
|
ES3022990T3
(en)
|
2019-12-06 |
2025-05-29 |
Prec Biosciences Inc |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
CN117736207A
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
JP2023516372A
(ja)
|
2020-03-02 |
2023-04-19 |
プロジェニア インコーポレイテッド |
病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
|
|
TWI845826B
(zh)
|
2020-03-20 |
2024-06-21 |
美商基利科學股份有限公司 |
4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
|
|
MX2022013619A
(es)
|
2020-05-01 |
2022-11-16 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina que inhiben cd73.
|
|
EP4153181A1
(en)
|
2020-05-21 |
2023-03-29 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
CA3181690A1
(en)
|
2020-06-25 |
2021-12-30 |
Chienhung CHOU |
Capsid inhibitors for the treatment of hiv
|
|
IL299508A
(en)
|
2020-07-01 |
2023-02-01 |
Ars Pharmaceuticals Inc |
Anti-asgr1 antibody conjugates and uses thereof
|
|
EP4194006A4
(en)
|
2020-08-04 |
2024-12-04 |
Progeneer Inc. |
mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
|
|
WO2022031057A1
(ko)
|
2020-08-04 |
2022-02-10 |
성균관대학교산학협력단 |
활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도
|
|
US20230355750A1
(en)
|
2020-08-04 |
2023-11-09 |
Progeneer Inc. |
Kinetically acting adjuvant ensemble
|
|
MX2023001507A
(es)
|
2020-08-07 |
2023-03-06 |
Gilead Sciences Inc |
Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
US20220144923A1
(en)
|
2020-11-11 |
2022-05-12 |
Gilead Sciences, Inc. |
METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
|
|
AU2022253902A1
(en)
|
2021-04-10 |
2023-11-02 |
Genmab A/S |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Cd70結合劑、其結合物及其使用方法
|
|
TW202348237A
(zh)
|
2021-05-13 |
2023-12-16 |
美商基利科學股份有限公司 |
TLR8調節化合物及抗HBV siRNA療法之組合
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117480155A
(zh)
|
2021-06-23 |
2024-01-30 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
CN117377671A
(zh)
|
2021-06-23 |
2024-01-09 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023076983A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ, インコーポレイテッド |
Cd73化合物
|
|
WO2023102523A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
CN118355020A
(zh)
|
2021-12-03 |
2024-07-16 |
吉利德科学公司 |
Hiv病毒感染的治疗性化合物
|
|
FI4445900T3
(fi)
|
2021-12-03 |
2025-08-05 |
Gilead Sciences Inc |
Terapeuttisia yhdisteitä hiv-virusinfektiota varten
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
AU2022419982A1
(en)
|
2021-12-22 |
2024-06-06 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
|
TW202346277A
(zh)
|
2022-03-17 |
2023-12-01 |
美商基利科學股份有限公司 |
Ikaros鋅指家族降解劑及其用途
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TWI856796B
(zh)
|
2022-04-06 |
2024-09-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
PE20250157A1
(es)
|
2022-04-21 |
2025-01-22 |
Gilead Sciences Inc |
Compuestos de modulacion de kras g12d
|
|
EP4547659A1
(en)
|
2022-07-01 |
2025-05-07 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
CN119384415A
(zh)
|
2022-07-01 |
2025-01-28 |
吉利德科学公司 |
Cd73化合物
|
|
EP4554628A1
(en)
|
2022-07-12 |
2025-05-21 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
CA3265134A1
(en)
|
2022-08-26 |
2024-02-29 |
Gilead Sciences, Inc. |
DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024076915A1
(en)
|
2022-10-04 |
2024-04-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
KR20250167002A
(ko)
|
2023-04-11 |
2025-11-28 |
길리애드 사이언시즈, 인코포레이티드 |
Kras 조절 화합물
|
|
AU2024259111A1
(en)
|
2023-04-19 |
2025-10-16 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
US20250042926A1
(en)
|
2023-05-31 |
2025-02-06 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv
|
|
US20250011352A1
(en)
|
2023-05-31 |
2025-01-09 |
Gilead Sciences, Inc. |
Solid forms
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
US20250120989A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
WO2025080863A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250127801A1
(en)
|
2023-10-11 |
2025-04-24 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
US20250296992A1
(en)
|
2024-01-10 |
2025-09-25 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025184452A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
WO2025184609A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
WO2025184447A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025260028A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|